menu
    • menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Cheplapharm"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Cheplapharm"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Candesartan Cilexetil","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Apontis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Apontis Pharma \/ Midas Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Atacand

    Menu

    Atacand

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apontis Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Apontis Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Midas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intel...

                            Details : The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hyperten...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Midas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AstraZeneca

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Cheplapharm Arzneimittel Gmbh

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed

                            Details : AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapha...

                            Brand Name : Atacand

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2021

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Cheplapharm Arzneimittel Gmbh

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AstraZeneca

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Cheplapharm Arzneimittel Gmbh

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries

                            Details : AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.

                            Brand Name : Atacand

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 30, 2020

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Cheplapharm Arzneimittel Gmbh

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth